title: [Results of postoperative radiochemotherapy of glioblastoma multiforme].
abstract: Glioblastoma multiforme has one of the worst prognoses of all cancers. A substantial progression in its treatment has been achieved only eight years ago when a new adjuvant radiochemotherapy regimen containing temozolomid has been introduced to the clinical practice. In this paper we evaluate the treatment results in adjuvant radiochemotherapy of glioblastoma carried out by two neurosurgery and oncology centers in Budapest, Hungary and we compared our results to the data of the reference phase III registration trial of the EORTC/NCIC. We analyzed the data of 210 patients treated for glioblastoma between 2005 and 2013. The primary endpoints of our study were overall survival and side effects. We studied and statistically analyzed the influence of multiple factors on survival. We compared our results with the data of the reference study and other results published in the literature. The median follow-up for the surviving patients in our study was 52 months. The median age of our patients was 58 (18-79) years. Seventy-two women and 138 men have been treated. The median overall survival was 17 (3-96) months, the progression-free survival 11 (3-96) months. The radiochemotherapy phase was completed in 95.2% and the monotherapy phase in 68% of all cases.Univariate analysis showed that age, ECOG status and RPA class had significant influence on survival. In multivariate analysis only RPA class remained statistically significant (RR 1.86, 95% CI 1.14-3.05). The proportion of grade III and worse side effects during the chemoradiation phase was 3.8% and in the monotherapy phase 1.9%. These were hematological side effects only. Serious hematological sequelae occurred nearly exclusively in women. Comparing to the reference study the demographic distribution of the patients was similar in our study but among our patients there were less patients with unfavorable prognosis (ECOG 2 or RPA V), and it resulted in a longer median survival than in the original trial (17 vs. 14.6 months). With this analysis of our patients treated according to the Stupp-protocol for glioblastoma multiforme we validated the results of the original EORTC/NCIC study in a Hungarian patient population. Moreover, this comparison proves that the comprehensive Hungarian neuro-oncology service is not at all inferior when compared to any of the developed countries in Europe.
authors.affiliation: Országos Onkológiai Intézet, Budapest, Hungary. lovey@oncol.hu.
authors.forename: József
authors.initials: J
authors.lastname: Lövey
authors.affiliation: Országos Klinikai Idegtudományi Intézet, Budapest, Hungary.
authors.forename: Imre
authors.initials: I
authors.lastname: Fedorcsák
authors.affiliation: Országos Onkológiai Intézet, Budapest, Hungary. lovey@oncol.hu.
authors.forename: András
authors.initials: A
authors.lastname: Bajcsay
authors.affiliation: Országos Klinikai Idegtudományi Intézet, Budapest, Hungary.
authors.forename: László
authors.initials: L
authors.lastname: Sipos
authors.affiliation: Onkoterápiás Intézet, Pécsi Tudományegyetem ÁOK, Pécs, Hungary.
authors.forename: László
authors.initials: L
authors.lastname: Mangel
authors.affiliation: Országos Onkológiai Intézet, Budapest, Hungary. lovey@oncol.hu.
authors.forename: Miklós
authors.initials: M
authors.lastname: Kásler
authors.affiliation: Országos Klinikai Idegtudományi Intézet, Budapest, Hungary.
authors.forename: Attila
authors.initials: A
authors.lastname: Bagó
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006814:Hungary; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D012189:Retrospective Studies; D012737:Sex Factors; D016019:Survival Analysis; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003606:Dacarbazine; D000077204:Temozolomide